Search

Your search keyword '"Kearsley-Fleet, Lianne"' showing total 27 results
Start Over Author "Kearsley-Fleet, Lianne" Publisher oxford university press (oup)
27 results on '"Kearsley-Fleet, Lianne"'

7. OA01 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

Author

Machado, Pedro M, primary, Lawson-Tovey, Saskia, additional, Strangfeld, Anja, additional, Mateus, Elsa, additional, Hyrich, Kimme, additional, Gossec, Laure, additional, Carmona, Loreto, additional, Rodrigues, Ana, additional, Raffeiner, Bernd, additional, Duarte, Cátia, additional, Hachulla, Eric, additional, Veillard, Eric, additional, Strakova, Eva, additional, Burmester, Gerd R, additional, Yardimci, Gozde K, additional, Gómez-Puerta, José A, additional, Zepa, Julija, additional, Kearsley-Fleet, Lianne, additional, Trefond, Ludovic, additional, Cunha, Maria M, additional, Mosca, Marta, additional, Cornalba, Martina, additional, Soubrier, Martin, additional, Roux, Nicolas, additional, Brocq, Olivier, additional, Durez, Patrick, additional, Conway, Richard, additional, Goulenok, Tiphaine, additional, Bijlsma, Johannes W. J, additional, McInnes, Iain, additional, and Mariette, Xavier, additional

Published
2022
Full Text
View/download PDF

10. Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra

Author

Kearsley-Fleet, Lianne, Beresford, Michael W, Davies, Rebecca, De Cock, Diederik, Baildam, Eileen, Foster, Helen E, Southwood, Taunton R, Thomson, Wendy, Hyrich, Kimme L, Dis, Biologics Children Rheumatic, and Public Health Sciences

Subjects
Male, Time Factors, Epidemiology, Arthritis, Antirheumatic Agents/therapeutic use, Outcome measures, Severity of Illness Index, Biologic Therapies, chemistry.chemical_compound, 0302 clinical medicine, Pharmacology (medical), Arthritis, Juvenile/drug therapy, 030212 general & internal medicine, Child, skin and connective tissue diseases, Statistics, Induction Chemotherapy, Clinical Science, Treatment Outcome, Antibodies, Monoclonal, Humanized/therapeutic use, statistics, Antirheumatic Agents, Child, Preschool, Cohort, epidemiology, Female, Biological Products/therapeutic use, medicine.drug, musculoskeletal diseases, medicine.medical_specialty, Antibodies, Monoclonal, Humanized, Interleukin 1 Receptor Antagonist Protein/therapeutic use, outcome measures, 03 medical and health sciences, Tocilizumab, Rheumatology, biologic therapies, Internal medicine, Severity of illness, medicine, Humans, Juvenile Idiopathic Arthritis, JIA, 030203 arthritis & rheumatology, Biological Products, Anakinra, business.industry, Induction chemotherapy, medicine.disease, Arthritis, Juvenile, Interleukin 1 Receptor Antagonist Protein, Logistic Models, chemistry, Macrophage activation syndrome, business
Abstract

Objectives To investigate real-world short-term outcomes among patients with systemic JIA starting tocilizumab or anakinra. Methods This analysis included all systemic JIA patients within the UK Biologics for Children with Rheumatic Diseases study starting tocilizumab or anakinra between 2010 and 2016. Disease activity was assessed at baseline and one year. At one year the following outcomes were assessed: minimal disease activity, clinically inactive disease, 90% ACR Paediatric response (ACRPedi90). Univariable logistic regression was used to identify baseline characteristics associated with these outcomes. Multiple imputation was used to account for missing data. Results Seventy-six systemic JIA patients were included (54 tocilizumab; 22 anakinra). More patients starting anakinra as their first biologic compared with tocilizumab (86% vs 63%; P = 0.04), with shorter disease duration (1 vs 2 years; P = 0.003) and higher frequency of prior macrophage activation syndrome (37% vs 8%; P = 0.004). Overall, at one year, 42% achieved ACRPedi90, 51% minimal disease activity, and 39% clinically inactive disease, with similar responses seen between the two drugs. Response was not associated with baseline disease characteristics. Fifteen (20%) patients stopped biologic treatment by one year. Treatment survival was better with tocilizumab (89% at one year vs 59% anakinra; P = 0.002), with three stopping for anakinra injection-related problems. Conclusion In this real-world cohort of patients with systemic JIA receiving tocilizumab or anakinra, approximately half achieved a minimal disease state by one year. Treatment responses appeared similar between the two therapies albeit with better persistence observed with tocilizumab.

Published
2018

12. Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom

Author

Kearsley-Fleet, Lianne, primary, Sampath, Sunil, additional, McCann, Liza J, additional, Baildam, Eileen, additional, Beresford, Michael W, additional, Davies, Rebecca, additional, De Cock, Diederik, additional, Foster, Helen E, additional, Southwood, Taunton R, additional, Thomson, Wendy, additional, and Hyrich, Kimme L, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results